Akihiro Matsunaga

Akihiro Matsunaga

Auto-generated profile, based on publicly available information

Akihiro Matsunaga

Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MMMomoko Morishita
Momoko Morishita
MSManabu Suzuki
Manabu Suzuki
AMAkihiro Matsunaga
Akihiro Matsunaga
KIKeishi Ishizhima
Keishi Ishizhima
TYTsukasa Yamamoto
Tsukasa Yamamoto
HSHaruhito Sugiyama
Haruhito Sugiyama

1 July 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MIMakoto Inada
Makoto Inada
MIMasahiro Ishikane
Masahiro Ishikane
MTMari Terada
Mari Terada
AMAkihiro Matsunaga
Akihiro Matsunaga
KMKenji Maeda
Kenji Maeda
NONorio Ohmagari
Norio Ohmagari

11 May 2023 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
SSSho Saito
Sho Saito
SKSatoshi Kutsuna
Satoshi Kutsuna
IAImamura Akifumi
Imamura Akifumi
RHRyota Hase
Ryota Hase
RORentaro Oda
Rentaro Oda
HMHiroaki Mitsuya
Hiroaki Mitsuya

27 February 2023 in Hepatology Communications
Verified
Journal Article
Open access
TTTomoki Takashina
Tomoki Takashina
AMAkihiro Matsunaga
Akihiro Matsunaga
YSYukiko Shimizu
Yukiko Shimizu
Tetsushi SakumaTetsushi Sakuma
Tetsushi Sakuma
TOTadashi Okamura
Tadashi Okamura
YIYukihito Ishizaka
Yukihito Ishizaka
Export Background: Cells of interest can be prepared from somatic cells by forced expression of lineage-specific transcription factors, but it is required to establish a vector-free system for their clinical use. Here, we report a protein-based artificial transcription system for engineering hepatocyte-like cells from human umbilical cord-derived mesenchymal stem cells (MSCs). Methods: MSCs were treated for 5 days with 4 artificial transcription factors (4F), which targeted hepatocyte nuclear factor (HNF)1α, HNF3γ, HNF4α, and GATA-binding protein 4 (GATA4). Then, engineered MSCs (4F-Heps) were subjected to epigenetic analysis, biochemical analysis and flow cytometry analysis with antibodies to marker proteins of mature hepatocytes and hepatic progenitors such as delta-like homolog 1 (DLK1) and trophoblast cell surface antigen 2 (TROP2). Functional properties of the cells were also examined by injecting them to mice with lethal hepatic failure. Results: Epigenetic analysis revealed that a 5-day treatment of 4F upregulated the expression of genes involved in hepatic differentiation, and repressed genes related to pluripotency of MSCs. Flow cytometry analysis detected that 4F-Heps were composed of small numbers of mature hepatocytes (at most 1%), bile duct cells (~19%) and hepatic progenitors (~50%). Interestingly, ~20% of 4F-Heps were positive for cytochrome P450 3A4, 80% of which were DLK1-positive. Injection of 4F-Heps significantly increased survival of mice with lethal hepatic failure, and transplanted 4F-Heps expanded to more than 50-fold of human albumin-positive cells in the mouse livers, well consistent with the observation that 4F-Heps contained DLK1-positive and/or TROP2-positive cells. Conclusion: Taken together with observations that 4F-Heps were not tumorigenic in immunocompromised mice for at least 2 years, we propose that this artificial transcription system is a versatile tool for cell therapy for hepatic failures.

2 January 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAkihiro Matsunaga
Akihiro Matsunaga
NANaokatsu Ando
Naokatsu Ando
YYYuko Yamagata
Yuko Yamagata
MSMari Shimura
Mari Shimura
HGHiroyuki Gatanaga
Hiroyuki Gatanaga
YIYukihito Ishizaka
Yukihito Ishizaka
Background: Despite effective antiretroviral therapy, patients with human immunodeficiency virus type-1 (HIV) suffer from a high frequency of malignancies, but related risk factors remain elusive. Here, we focused on blood-circulating viral protein R (Vpr) of HIV, which induces proinflammatory cytokine production and genotoxicity by exogenous functions. Methods and findings: A total 404 blood samples of HIV patients comprising of 126 patients with malignancies (tumor group) and 278 patients without malignancies (non-tumor group), each of 96 samples was first selected by one-to-one propensity score matching. By a detergent-free enzyme-linked immunosorbent assays (detection limit, 3.9 ng/mL), we detected Vpr at a higher frequency in the matched tumor group (56.3%) than in the matched non-tumor group (39.6%) (P = 0.030), although there was no different distribution of Vpr levels (P = 0.372). We also detected anti-Vpr immunoglobulin (IgG), less frequently in the tumor group compared with the tumor group (22.9% for tumor group vs. 44.8% for non-tumor group, P = 0.002), and the proportion of patients positive for Vpr but negative of anti-Vpr IgG was significantly higher in the tumor group than in the non-tumor group (38.6% vs. 15.6%, respectively, P < 0.001). Additionally, Interleukin-6 (IL-6), the levels of which were high in HIV-1 infected patients (P < 0.001) compared to non-HIV-infected individuals, was significantly higher in advanced cases of tumors (P < 0.001), and IL-6 level was correlated with Vpr in the non-tumor group (P = 0.010). Finally, multivariate logistic regression analysis suggested a positive link of Vpr with tumor occurrence in HIV patients (P = 0.002). Conclusion: Vpr and IL-6 could be risk factors of HIV-1 associated malignancies, and it would be importance to monitor these molecules for well managing people living with HIV-1.

9 March 2022 in CEN Case Reports
Verified
Journal Article
Open access
PDF file
HBHiroko Beppu
Hiroko Beppu
TOToshie Ogawa
Toshie Ogawa
MIMasahiro Ishikane
Masahiro Ishikane
TKTomoko Kawanishi
Tomoko Kawanishi
TFTatsuya Fukuda
Tatsuya Fukuda
SWSachiko Wakai
Sachiko Wakai
Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.